Each Creon capsule contains 300 mg of pancreatin obtained from pancreatic glands and is composed of lipase (8000 FIP units), amylase (9000 FIP units) and protease (450 FIP units)

 

Creon is a new form of pancreatic replacement therapy which combines the features of fast, homogeneous distribution in the stomach with complete protection against inactivation by gastric juices. The micro-spheres mix homogeneously with the chyme in the stomach and pass into the small intestine, where they dissolve rapidly in the alkaline pH, thus releasing the enzymes rapid action in the small intestine is thus ensured.

 

Pancreatic exocrine insufficiency, caused by cystic fibrosis, chronic pancreatitis and after pancreatic surgery.

 

Creon¨ is contra-indicated during the early stages of acute pancreatitis or in those patients with a known allergy to pancreatin.

 

None

 

The incidence of drug related adverse effects is very low (<1 %); the most common are diarrhoea, constipation, gastric discomfort, nausea and skin reactions.

 

Initially 1 or 2 capsules with meals or snacks, then the dose should be adjusted depending on individual requirements.

 

for PDF files, a free viewer is downloadable on the Adobe Systems' World Wide Website